Ledderhose disease is a benign but often painful condition in which firm nodules grow along the thick band of connective tissue on the sole of the foot, known as the plantar fascia. Sometimes called plantar fibromatosis, it is relatively rare, affects men more often than women, and tends to show up in middle age. The condition shares a family tree with Dupuytren’s disease of the hand, and many of the same risk factors and treatment strategies overlap. Although the nodules are not cancerous and many people live with mild cases comfortably, the disease can make every step hurt when it progresses, and deciding among the growing list of treatment options is not straightforward.
What Actually Grows in the Foot
The plantar fascia is a tough strip of tissue running from the heel bone to the base of the toes. It supports the arch and absorbs shock during walking. In Ledderhose disease, cells called fibroblasts and myofibroblasts proliferate abnormally within this tissue, forming dense nodules that are firmly attached to the fascia. The nodules sit on the non-weight-bearing part of the arch at first, which is why early cases often go unnoticed. As they enlarge, they can press into surrounding structures and become painful with every step.
The disease progresses through three recognized phases. First comes a proliferative phase, during which fibroblast activity ramps up and cells multiply rapidly. This gives way to an active phase in which the actual nodules form and become palpable. Finally, a residual phase sets in, characterized by collagen deposition, scar tissue formation, and, in some cases, tissue contracture. Unlike Dupuytren’s disease in the hand, where contracture of the fingers is a hallmark problem, plantar fibromatosis usually does not lead to contracture of the toes. The main issue is pain and difficulty walking.1Journal of Pathology and Translational Medicine. Palmar and plantar fibromatosis: a review – Section: ETIOLOGY AND PATHOGENESIS
About a quarter of cases are bilateral, meaning nodules develop in both feet.2Journal of Pathology and Translational Medicine. Palmar and plantar fibromatosis: a review – Section: ETIOLOGY AND PATHOGENESIS When that happens, treatment decisions get more complicated because both feet need attention simultaneously, and surgical recovery becomes harder to manage.
Who Gets It and What Raises the Risk
The exact cause of Ledderhose disease remains unclear, but several risk factors have been linked to it. These include diabetes, liver disease, alcohol consumption, the use of anticonvulsant medications, a history of trauma to the foot, and even frozen shoulder.3PubMed Central. Ledderhose’s Disease: An Up-to-Date Review of a Rare Non-Malignant Disorder The thread connecting many of these risk factors seems to involve chronic inflammation and abnormal tissue repair signaling, but researchers have not pinned down a single pathway that explains every case.
There is a genetic component, though the picture is still being pieced together. In one family study, researchers looking at relatives affected by both Dupuytren’s and Ledderhose disease identified a novel variant in the ASTE1 gene and a rare variant in the OR51A7 gene that co-segregated with the affected family members.4MDPI. Dupuytren’s and Ledderhose Diseases in a Family with LMNA-Related Cardiomyopathy and a Novel Variant in the ASTE1 Gene – Section: 3. Results / 3.3 Exome Sequencing and Co-Segregation for DD/LD-Associated Variants This doesn’t mean those specific genes “cause” the disease in every patient, but it supports the idea that susceptibility runs in families. If you have close relatives with Dupuytren’s or Ledderhose disease, your own risk is probably elevated.
The Dupuytren’s Connection
Ledderhose disease does not exist in isolation. It belongs to a family of fibroproliferative disorders that also includes Dupuytren’s contracture in the hand, Peyronie’s disease affecting penile tissue, and knuckle pads on the fingers. Having one of these conditions raises the likelihood of developing another. In a study of 730 men with Dupuytren’s disease, surgeons found Ledderhose disease in about 16% of them, while the patients themselves reported it at a rate of 22%.5PubMed. Prevalence of Peyronie and Ledderhose Diseases in a Series of 730 Patients with Dupuytren Disease The gap between those numbers hints that the condition is underdiagnosed when doctors aren’t specifically looking for it. If you have Dupuytren’s, it’s worth mentioning any foot lumps to your doctor, even if they seem unrelated.
How It Changes the Way You Walk
Painful nodules don’t just cause localized discomfort; they change gait mechanics in measurable ways. A case-control study comparing people with painful Ledderhose disease to healthy controls found that affected patients shift pressure toward the heel and toes while offloading the midfoot during walking.6PubMed. Effect of painful Ledderhose disease on dynamic plantar foot pressure distribution during walking: a case-control study In other words, patients unconsciously alter their stride to avoid pressing on the nodules. Over time, this compensatory pattern can strain other parts of the foot, knee, or hip, turning what started as a foot problem into a more widespread biomechanical issue.
How It Is Diagnosed
Most cases begin with a physical exam: a doctor feels a firm, non-tender or mildly tender lump on the sole of the foot. The lump is typically attached to the plantar fascia rather than floating freely, and it doesn’t move much when pushed side to side. But a physical exam alone can’t rule out other causes of foot masses, so imaging usually follows.
On ultrasound, a plantar fibroma typically appears as a well-defined, slightly dark nodule with a maximum diameter of roughly one centimeter, showing a few thin bright internal bands. It adheres along the long axis of the plantar fascia, has clear-cut margins, and shows no calcifications or fluid collections inside. Color Doppler usually reveals no blood flow within the nodule.7PubMed Central. Ledderhose Disease: Clinical, Radiological, and Anatomopathological Findings MRI provides additional detail when surgery is being considered: the nodule appears as a well-defined mass continuous with the plantar fascia, dark on both T1-weighted and T2-weighted sequences.8PubMed Central. Imaging of plantar fascia disorders: findings on plain radiography, ultrasound and magnetic resonance imaging The dark signal on MRI reflects the dense fibrous composition of the nodule. Brighter areas on T2 images can suggest more active, cellular disease rather than mature scar tissue, which helps guide treatment decisions.
One reason imaging matters is differential diagnosis. Not every lump on the bottom of the foot is a plantar fibroma. Giant cell tumors, ganglion cysts, nerve tumors, and even certain soft tissue sarcomas can present similarly. The imaging characteristics of plantar fibromatosis are distinctive enough that a confident diagnosis can usually be made without a biopsy, sparing patients an unnecessary procedure on a weight-bearing surface.
Starting with Conservative Treatment
Because the disease is benign and many nodules remain small and painless for years, the first-line approach is usually conservative. This includes cushioned insoles or custom orthotics designed to redistribute pressure away from the nodule, physical therapy to maintain flexibility, and sometimes corticosteroid injections to reduce inflammation and pain. Verapamil, a calcium channel blocker typically used for heart conditions, has also been applied topically or injected directly into nodules, though evidence for its effectiveness in plantar fibromatosis specifically remains limited.9PubMed Central. The etiology, evaluation, and management of plantar fibromatosis
For many patients, conservative measures are enough to manage the condition indefinitely. The challenge arises when nodules grow, multiply, or become painful enough to interfere with daily activities despite these interventions. At that point, more aggressive options come into play.
Radiation Therapy for Early Disease
Radiation therapy is one of the more thoroughly studied non-surgical options for Ledderhose disease, and the evidence behind it has strengthened considerably. A typical protocol delivers low-dose radiation in two separate courses of five daily sessions, with each session delivering 3 Gy for a total of 30 Gy over several weeks. The goal is not to destroy the nodule but to suppress the overactive fibroblasts that drive its growth.
A long-term follow-up study of patients treated with this approach found that pain scores dropped from a mean of 5.7 before treatment to 1.7 afterward. About 41% of treated feet achieved complete pain relief, another 37% had partial improvement, and 22% experienced no change. None got worse. Nearly four out of five patients said they were satisfied with the results.10PubMed. Radiotherapy for patients with Ledderhose disease: Long-term effects, side effects and patient-rated outcome Separately, a study focused on early-stage disease found that after a median follow-up of nearly two years, none of the treated patients experienced progression of their lesions, suggesting radiation can stabilize the disease and potentially prevent the need for surgery.11PubMed. Radiation therapy for early stages of morbus Ledderhose
The strongest evidence comes from the LedRad study, a prospective randomized trial that compared real radiation to sham radiation. At 12 months, patients in the radiation group had significantly lower pain scores than those who received the sham treatment, and at 18 months the gap widened further. Pain relief was reported by 74% of the radiation group versus 56% of the sham group. Quality-of-life scores were also higher, and patients in the radiation group walked faster and with a higher step rate during barefoot testing. Side effects were mostly mild: skin redness, dryness, and occasional burning, with 87% of side effects resolving within 18 months.12PubMed. Radiotherapy for Ledderhose disease: Results of the LedRad-study, a prospective multicentre randomised double-blind phase 3 trial This trial matters because it’s one of the few randomized controlled studies in the field, offering a level of evidence rare for a rare disease.
Radiation works best in earlier stages, when fibroblast activity is still high and the tissue hasn’t yet hardened into dense scar. For patients with large, mature, fibrotic nodules, the benefit may be more limited. Younger patients and those who might want to conceive should discuss the low but non-zero theoretical risks of pelvic radiation scatter with their physician, though the doses used are far below those in cancer treatment.
Shockwave Therapy
Extracorporeal shockwave therapy (ESWT) uses focused sound waves to disrupt tissue and stimulate healing. In a small study of patients with painful plantar fibromatosis, pain dropped from a mean score of 6 at baseline to 2 after two weeks and 1 after three months. All patients noticed softening of the nodules, and no adverse effects were reported.13PubMed Central. High-energy focussed extracorporeal shockwave therapy reduces pain in plantar fibromatosis (Ledderhose’s disease)
A longer follow-up study using ultrasound imaging confirmed that fibroma thickness decreased significantly after shockwave treatment, shrinking from an average of about 4.4 mm to 2.6 mm. However, the length and width of the fibromas did not change significantly, and no cases achieved complete resolution.14PLoS ONE. Follow-up of clinical and sonographic features after extracorporeal shock wave therapy in painful plantar fibromatosis In practical terms, shockwave therapy can make the nodules thinner and less painful, but it won’t make them disappear. That’s still a meaningful outcome for someone who wants to avoid surgery and just needs to get through a day on their feet with less pain.
Collagenase Injections
Collagenase clostridium histolyticum (CCH) is an enzyme that breaks down collagen, the structural protein that makes up the bulk of plantar fibromas. It gained attention as a treatment for Dupuytren’s contracture and has been used off-label for Ledderhose disease, though the evidence so far consists of case reports rather than controlled trials.
The results of those individual cases are encouraging. One report described a young woman with recurrent plantar fibromatosis after a previous surgery who remained symptom-free almost four years after a single CCH injection.15PubMed. The Effects of Collagenase Clostridium histolyticum on Plantar Fibromatosis: A Case Study Another report documented successful treatment of a pediatric patient who had failed prior surgery, with sustained resolution of symptoms at one year.16PubMed Central. The successful use of collagenase for Ledderhose disease (plantar fibromatosis) in a paediatric patient: a case report A case of bilateral disease treated with collagenase injections showed that the patient could walk normally immediately after the procedure, with no recurrence at over a year of follow-up.17PubMed Central. Unusual Intranodular Collagenase Injection: A Case of Bilateral Ledderhose Disease
The appeal of collagenase is that it’s minimally invasive: a single injection into the nodule, performed in an office setting, with little recovery time. The limitation is that broader evidence is lacking. Case reports can’t tell us about recurrence rates across large groups, optimal dosing, or which patients are most likely to benefit. Additionally, the commercial availability of CCH has been inconsistent in some markets, making access uncertain.
Cryoablation
Another newer approach involves percutaneous cryoablation, where a small probe is inserted into the nodule under ultrasound guidance and the tissue is frozen. Early experience with this technique suggests it is safe and produces near-complete symptom improvement.18PubMed. Percutaneous Ultrasound-Guided Cryoablation for Symptomatic Plantar Fibromas The procedure can be done as an outpatient with local anesthesia and leaves minimal scarring on the sole of the foot, which is an advantage over open surgery. However, as with collagenase, the published evidence remains preliminary and long-term recurrence data are sparse.
When Surgery Becomes Necessary
Surgery is generally reserved for patients who have tried conservative and non-surgical treatments without adequate relief. The operation involves removing the nodule along with varying amounts of surrounding fascia. How much tissue gets removed turns out to be the most important predictor of whether the disease comes back.
A systematic review found that recurrence rates differ dramatically depending on the extent of resection. Simple local excision of just the nodule carries a recurrence rate of about 67%. A wider resection that removes the nodule plus a margin of surrounding tissue brings recurrence down to around 42%. A full or near-total fasciectomy, in which most of the plantar fascia is removed, drops it further to about 27%.19PubMed. Recurrence Rate After Wide Resection of Plantar Fibromatosis: A Case Series and Systematic Literature Review These numbers illustrate the frustrating trade-off at the heart of surgical treatment: removing more tissue lowers recurrence but increases the risk of complications, including wound-healing problems, nerve damage, and changes to foot biomechanics that can cause their own chronic pain.
Recovery from plantar surgery is slow. The sole of the foot bears the full weight of the body, and surgical wounds here are notoriously difficult to heal. Patients can expect several weeks of limited weight-bearing and months before they return to full activity. For people with bilateral disease or those whose livelihood depends on being on their feet, the downtime alone can be a significant factor in the decision.
The TNF-Alpha Question
Tumor necrosis factor alpha (TNF-α) is an inflammatory molecule that plays a role in fibroblast-to-myofibroblast conversion, the cellular transformation that drives nodule growth in fibromatoses. This has led to interest in whether blocking TNF-α with drugs already used for conditions like rheumatoid arthritis and inflammatory bowel disease could treat or prevent plantar fibromatosis.
The clinical reality has been mixed. A case report described two patients with spondyloarthritis who actually developed plantar fibromatosis while taking anti-TNF drugs (adalimumab and etanercept). When the drugs were stopped, the nodules shrank and stabilized.20Joint Bone Spine. Active plantar fibromatosis occurring under anti-TNFα therapy for spondyloarthritis That’s the opposite of what you’d expect if TNF-α were simply driving the disease. More recently, laboratory work on Dupuytren’s tissue found that anti-TNF treatment did not reduce the synthesis of the type I collagen that characterizes fibrotic tissue, suggesting that blocking TNF-α alone is unlikely to prevent the pathological collagen accumulation at the core of these diseases.21PubMed Central. Active synthesis of type I collagen homotrimer in Dupuytren’s fibrosis is unaffected by anti-TNF-α treatment The relationship between TNF-α and fibromatosis is clearly more complicated than a simple on-off switch, and this pathway may not be the therapeutic target researchers once hoped.
Living with a Rare Condition
One of the most frustrating aspects of Ledderhose disease is that its rarity means many general practitioners have never seen a case. Patients frequently report being told they have a cyst, a callus, or plantar fasciitis before getting the correct diagnosis, sometimes after years of misdirected treatment. If you’ve been told you have an unexplained lump on the sole of your foot that isn’t going away, requesting an ultrasound is a reasonable first step. The characteristic imaging appearance is distinctive enough that a radiologist can usually make the call without invasive testing.
Support communities, mostly online, have become an important resource for people navigating this diagnosis. Because the disease is uncommon, patients often arrive at specialist consultations knowing as much about it as some of the clinicians they see. That isn’t a criticism of doctors; it’s simply a consequence of a condition that most medical schools cover in a single line if they cover it at all. Bringing published evidence to appointments, especially regarding newer options like radiation or shockwave therapy, can help ensure the conversation covers the full range of treatments rather than jumping straight to surgery or being dismissed as something to just live with.